fashion -WSS

fashion

author：leisure time 2025-09-28 04:58:48 - browse：3891

Maze Therapeutics CEO Jason Coloma Courtesy

After seeing its last deal go bust in the face of regulatory scrutiny, Maze Therapeutics has found another suitor for its experimental Pompe disease treatment.

Bay Area-based Maze and Shionogi said Friday that the Japanese pharma company had licensed the drug, called MZE001, with an upfront payment of $150 million. The global deal includes additional, undisclosed payments if the oral medication, which is in clinical testing, meets certain regulatory and commercial goals.

Last year, Sanofi, the French pharma giant, was set to pay $150 million in cash and stock to Maze before the transaction fell apart.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Ransomware attacks on hospitals: Study outlines patient impact

WSS

Verily hires former Apple Health leader as chief scientific officer

A daunting task: navigating dual Medicare, Medicaid eligibility

ProMED, early warning system on disease outbreaks, in peril

ProMED, early warning system on disease outbreaks, in peril

PBM reforms clear House panel

'Ancient DNA,' 23andMe reveal African American ancestries

explore

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Guidelines to prevent youth baseball injuries need more muscle

Gain of function research would be limited under House proposal

United colonoscopy coverage change 'may cost lives,' doctors say

Anthos stroke drug appears safer than common blood thinner

Sports medicine is finally prioritizing gender equality

Weight loss drug costs may need more research, senator suggests

Guidelines to prevent youth baseball injuries need more muscle

Childhood cancer progress stalls for Black, Hispanic kids: Report

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

In key trial, Verve's treatment lowers cholesterol levels in patients

hotspot

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

The drug industry sees a key ally in the Senate prevail

ER docs worry over extreme heat as a 'mass casualty event'

White House drug shortage group privately met with industry

World's first CRISPR

Why medical students are struggling with mental health

hotspot

entertainment

entertainment

focus